Research institution
Anhui Provincial Hospital Clinical Trials
Studies where Anhui Provincial Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 70Penile Squamous Cell Carcinoma (PSCC), Advanced Penile Cancer
Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum Chemotherapy
This is a single-center, single-arm, open-label, Phase 2 clinical trial (the SCOPE study) evaluating the efficacy, safety, and tolerability of sacituzumab tirumotecan (SKB264) combined with toripalimab as a second-line…
- Conditions
- Penile Squamous Cell Carcinoma (PSCC), Advanced Penile Cancer, Metastatic Penile Cancer, Locally Advanced Penile Cancer
- Trial name
- SCOPE (NCT07907861)
- Testing
- Sacituzumab Tirumotecan (SKB264), Toripalimab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Anhui Provincial Hospital
Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody)
Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
This is a randomized, controlled, multicenter clinical study to evaluate AK104 in FIGO 2018 stage III-IV ovarian cancer subjects who were assessed to be at high perioperative risk and/or unable to achieve R0 resection prior to…
- Conditions
- Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy
- Trial name
- NCT06542549
- Testing
- AK104
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Anhui Provincial Hospital
Aplastic Anaemia
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
To evaluate the safety and efficacy of Single Umbilical Cord blood transplantation (sUCBT) containing low dose ATG based conditioning regimen in the treatment of Aplastic Anemia (AA)
- Trial name
- NCT07885982
- Testing
- Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Anhui Provincial Hospital
Biliary Tract Cancer
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors
This is a prospective, multicenter, single-arm, phase II clinical study designed to explore the efficacy and safety of zanidatamab in combination with liposomal irinotecan and capecitabine as second-line therapy for HER2-positive…
- Trial name
- ZENITH (NCT07841873)
- Testing
- Zanidatamab
- Volunteers
- 15 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
This study will look at whether adding daily oral zinc supplements to targeted therapy plus immunotherapy may help people with unresectable or advanced hepatocellular carcinoma, a common type of liver cancer.
- Trial name
- ZINC-1LT/IOHCC (NCT07793695)
- Testing
- Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Colorectal Liver Metastases, Colorectal Neoplasms
Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline…
- Conditions
- Colorectal Liver Metastases, Colorectal Neoplasms, Liver Neoplasms
- Trial name
- NCT07830576
- Testing
- Multimodal Predictive Evaluation
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Anhui Provincial Hospital
Locally Advanced Cervical Cancer
Perioperative Adebrelimab for Locally Advanced Cervical Cancer
This prospective, single-center, single-arm, phase II study will evaluate perioperative adebrelimab in patients with locally advanced cervical cancer.
- Trial name
- ADE-LACC (NCT07811375)
- Testing
- Adebrelimab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma (HCC)
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy.
- Trial name
- NCT07782632
- Testing
- Baseline Liver Volume Volumetric Analysis
- Where
- China
- Volunteers
- 467 people
- Sponsor
- Anhui Provincial Hospital
Acute Graft-versus-host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell…
- Trial name
- NCT06294691
- Testing
- Time of stem cell infusion
- Where
- 6 sites in China
- Volunteers
- 198 people
- Sponsor
- Anhui Provincial Hospital
Cancer Treatment-induced Thrombocytopenia (CTIT)
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia
Evaluation of the Efficacy and Safety of Romiplostim N01 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (CTIT) in Patients with Leukemia
- Trial name
- NCT06898983
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Anhui Provincial Hospital